uniQure (NASDAQ:QURE) Downgraded by Wall Street Zen to Sell

Wall Street Zen downgraded shares of uniQure (NASDAQ:QURE) from a hold rating to a sell rating in a research note released on Saturday morning,Wall Street Zen reports.

Several other research firms have also recently weighed in on QURE. Wolfe Research raised shares of uniQure from a “peer perform” rating to an “outperform” rating and set a $65.00 price target on the stock in a report on Wednesday, July 29th. Weiss Ratings restated a “sell (e+)” rating on shares of uniQure in a research report on Friday, June 26th. The Goldman Sachs Group upped their target price on uniQure from $14.00 to $46.00 and gave the stock a “neutral” rating in a research note on Thursday, June 18th. Mizuho lifted their price target on uniQure from $35.00 to $68.00 and gave the company an “outperform” rating in a research report on Thursday, June 25th. Finally, Royal Bank Of Canada lifted their price target on uniQure from $35.00 to $65.00 and gave the company an “outperform” rating in a research report on Thursday, June 18th. Fourteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $65.00.

uniQure Price Performance

QURE stock opened at $44.50 on Friday. The firm has a 50 day moving average of $44.30 and a 200-day moving average of $30.34. The company has a current ratio of 10.01, a quick ratio of 10.01 and a debt-to-equity ratio of 0.15. uniQure has a 12 month low of $8.73 and a 12 month high of $71.50. The firm has a market capitalization of $3.09 billion, a P/E ratio of -11.10 and a beta of 0.94.

uniQure (NASDAQ:QURE) last posted its earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.40). uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%.The firm had revenue of $5.84 million for the quarter, compared to the consensus estimate of $5.45 million. During the same period last year, the company posted ($0.69) EPS. As a group, sell-side analysts predict that uniQure will post -3.82 earnings per share for the current fiscal year.

Insider Transactions at uniQure

In other uniQure news, Director Jack Kaye sold 21,167 shares of uniQure stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $46.44, for a total transaction of $982,995.48. Following the completion of the sale, the director owned 25,996 shares of the company’s stock, valued at $1,207,254.24. The trade was a 44.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Matthew Kapusta sold 21,082 shares of the company’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $45.16, for a total value of $952,063.12. Following the completion of the transaction, the chief executive officer owned 519,227 shares of the company’s stock, valued at $23,448,291.32. The trade was a 3.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 385,584 shares of company stock worth $16,737,722. Company insiders own 4.65% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Hennion & Walsh Asset Management Inc. boosted its stake in shares of uniQure by 107.3% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 142,113 shares of the biotechnology company’s stock valued at $6,546,000 after purchasing an additional 73,566 shares in the last quarter. Royal Bank of Canada grew its holdings in shares of uniQure by 26.0% during the 1st quarter. Royal Bank of Canada now owns 107,888 shares of the biotechnology company’s stock valued at $1,763,000 after purchasing an additional 22,248 shares during the last quarter. Kalehua Capital Management LLC purchased a new position in uniQure in the 1st quarter worth $4,760,000. UBS Group AG raised its position in uniQure by 139.7% in the 4th quarter. UBS Group AG now owns 491,454 shares of the biotechnology company’s stock worth $11,760,000 after purchasing an additional 286,465 shares during the period. Finally, Voss Capital LP boosted its position in uniQure by 68.0% during the fourth quarter. Voss Capital LP now owns 210,000 shares of the biotechnology company’s stock valued at $5,025,000 after buying an additional 85,000 shares during the period. 78.83% of the stock is currently owned by institutional investors.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.